Angiotensin receptor blockers: pharmacology, efficacy, and safety
- PMID: 21896150
- PMCID: PMC8108884
- DOI: 10.1111/j.1751-7176.2011.00518.x
Angiotensin receptor blockers: pharmacology, efficacy, and safety
Abstract
KEY POINTS AND PRACTICAL RECOMMENDATIONS: • The angiotensin receptor blockers are highly effective antihypertensive agents that are also particularly well tolerated. • There are no major differences in efficacy or other clinical characteristics among older drugs in this class, although some of the newer agents may more effectively reduce blood pressure than older agents. • Major randomized clinical trials have demonstrated that angiotensin receptor blockers provide significant outcomes benefits in conditions such as diabetic nephropathy, chronic heart failure or heart failure following myocardial infarction, hypertension with left ventricular hypertrophy and in patients whose histories of previous events or complicated diabetes puts them at high cardiovascular risk. • In treating hypertension, angiotensin receptor blockers can be used as first-line therapy or added at later stages of treatment titration. • These drugs are very effective in combination with thiazide diuretics or calcium channel blockers and there are several single-pill, fixed-dose combinations of angiotensin receptor blockers with hydrochlorothiazide, amlodipine, or aliskiren. These combinations can be given as initial therapy (where appropriate) or later in the course of treatment. Three-drug combinations (angiotensin receptor blocker plus amlodipine plus hydrochlorothiazide and angiotensin receptor blocker plus aliskiren plus hydrochlorothiazide) are also available.
© 2011 Wiley Periodicals, Inc.
Similar articles
-
Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic.Vasc Health Risk Manag. 2012;8:371-80. doi: 10.2147/VHRM.S28359. Epub 2012 Jun 11. Vasc Health Risk Manag. 2012. PMID: 22745561 Free PMC article. Review.
-
Treating essential hypertension. The first choice is usually a thiazide diuretic.Prescrire Int. 2014 Sep;23(152):215-20. Prescrire Int. 2014. PMID: 25325125 Review.
-
Thiazide and loop diuretics.J Clin Hypertens (Greenwich). 2011 Sep;13(9):639-43. doi: 10.1111/j.1751-7176.2011.00512.x. Epub 2011 Jul 27. J Clin Hypertens (Greenwich). 2011. PMID: 21896142 Free PMC article. Review.
-
Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.Trials. 2018 Feb 12;19(1):101. doi: 10.1186/s13063-017-2343-3. Trials. 2018. PMID: 29433578 Free PMC article.
-
50 years of thiazides: should thiazide diuretics be considered third-line hypertension treatment?Am J Ther. 2011 Nov;18(6):e244-54. doi: 10.1097/MJT.0b013e3181e90863. Am J Ther. 2011. PMID: 21436766 Review.
Cited by
-
A Comprehensive Review of Cardiovascular Disease Management: Cardiac Biomarkers, Imaging Modalities, Pharmacotherapy, Surgical Interventions, and Herbal Remedies.Cells. 2024 Sep 1;13(17):1471. doi: 10.3390/cells13171471. Cells. 2024. PMID: 39273041 Free PMC article. Review.
-
Lower Incidence of Hypoglycemia With Angiotensin Receptor Blocker Versus ACE Inhibitor Therapy in People With or Without Diabetes.Clin Diabetes. 2024 Spring;42(2):300-307. doi: 10.2337/cd23-0039. Epub 2024 Jan 12. Clin Diabetes. 2024. PMID: 38694239
-
Genetic Deletion of β-Arrestin 2 From the Subfornical Organ and Other Periventricular Nuclei in the Brain Alters Fluid Homeostasis and Blood Pressure.Hypertension. 2024 Jun;81(6):1332-1344. doi: 10.1161/HYPERTENSIONAHA.124.22874. Epub 2024 Apr 17. Hypertension. 2024. PMID: 38629290
-
The Renin Angiotensin System as a Therapeutic Target in Traumatic Brain Injury.Neurotherapeutics. 2023 Oct;20(6):1565-1591. doi: 10.1007/s13311-023-01435-8. Epub 2023 Sep 27. Neurotherapeutics. 2023. PMID: 37759139 Free PMC article. Review.
-
Rifampicin-induced hypertensive urgency: eyes see what the mind knows.BMJ Case Rep. 2023 May 31;16(5):e254699. doi: 10.1136/bcr-2023-254699. BMJ Case Rep. 2023. PMID: 37258052
References
-
- Ferrario CM. Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research. J Renin Angiotensin Aldosterone Syst. 2006;7:3–14. - PubMed
-
- Harrison DG, Gongora MC. Oxidative stress and hypertension. Med Clin North Am. 2009;93:621–635. - PubMed
-
- Savoia C, Schiffrin EL. Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. Clin Sci (Lond). 2007;112:375–384. - PubMed
-
- Ismail H, Mitchell R, McFarlane SI, Makaryus AN. Pleiotropic effects of inhibitors of the RAAS in the diabetic population: above and beyond blood pressure lowering. Curr Diab Rep. 2010;10:32–36. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
